Essential fatty acids in Huntington's disease

Nutrition

Volumn 20, Issue 10, 2004, Pages 942-947

  Das, Undurti N ^a,c   Vaddadi, Krishna S ^b  

^a UND Life Sciences   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c UND Life Sciences   (United States)

Author keywords

amyloid fibrils; apoptosis; docosahexaenoic acid; eicosapentaenoic acid; essential fatty acids; huntingtin; Huntington's disease; polyQ peptides; ubiquitin proteasome system

Indexed keywords

ESSENTIAL FATTY ACID;

AMINO TERMINAL SEQUENCE; CELL NUCLEUS; EXON; GENE MUTATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

EID: 4944230131     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2004.06.017     Document Type: Article

References (54)

1. Harper P.S. Huntington's disease. 1996;WB Saunders, London
2. Dragatsis I., Levine M.S., Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet. 26:2000;300-306
3. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet. 361:2003;1642-1644
4. Yang W., Dunlap J.R., Andrews R.B., Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet. 11:2002;2905-2917
5. Chen S., Berthelier V., Yang W., Wetzel R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J Mol Biol. 311:2001;173-182
6. Chen S., Wetzel R. Solubilization and disaggregation of polyglutamine peptides. Protein Sci. 10:2001;887-891
7. Scherzinger E., Sittler A., Schweiger K., et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci USA. 96:1999;4604-4609
8. Kazantsev A., Walker H.A., Slepko N., et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet. 30:2002;367-376
9. Sanchez I., Mahlke C., Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 421:2003;373-379
10. Nucifora F.C., Sasaki M., Peters M.F., et al. Interference by huntingtin and atophin-1 with CBP-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428
11. Bence N.F., Sampat R.M., Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 292:2001;1552-1555
12. Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci USA. 91:1994;5355-5358
13. Kazantsev A., Preisinger E., Dranovsky A., Goldgaber D., Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci USA. 96:1999;11404-11409
14. McCampbell A., Taylor J.P., Taye A.A., et al. CREB-binding protein sequestration by expanded polyglutamine. Hum Mol Genet. 9:2000;2197-2202
15. Shimohata T., Nakajima T., Yamada M., et al. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet. 26:2000;29-36
16. Steffan J.S., Kazantsev A., Spasic-Boskovic O., et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA. 97:2000;6763-6768
17. Luthi-Carter R., Strand A., Peters N.L., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 9:2000;1259-1271
18. Richfield E.K., Maguire-Zeiss K.A., Cox C., Gilmore J., Voorn P. Reduced expression of preproenkephalin in striated neurons from Huntington's disease patients. Ann Neurol. 37:1995;335-343
19. Ferrer I., Goutan E., Marin C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866:2000;257-261
20. Cha J.H., Frey A.S., Alsdorf S.A., et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Phil Trans R Soc Lond B Biol Sci. 354:1999;981-989
21. Menalled L., Zanjani H., MacKenzie L., et al. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 162:2000;328-342
22. Varani K., Rigamonti D., Sipione S., et al. Aberrant amplification of A92A receptor signaling in striatal cells expressing mutant huntingtin. FASEB J. 15:2001;1245-1247
23. Blum D., Hourez R., Galas M.C., Popoli P., Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2:2003;366-374
24. Salem N., Niebylski C.D. The nervous system has an absolute molecular species requirement for proper function. Mol Membr Biol. 12:1995;131-134
25. Fenton W.S., Hibbeln J., Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 47:2000;8-21
26. Das U.N. Essential fatty acids: biology and their clinical implications. Asian Pac J Pharmacol. 6:1991;317-330
27. Perez-Severiano F., Rios C., Segovia J. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862:2000;234-237
28. Vaddadi K.S. Essential fatty acids and neuroleptic drug induced tardive dyskinesia-preliminary clinical observations. IRCS Med Sci. 12:1984;678-679
29. Mellor J.E., Laugharne D.E.J., Peet M. Schizophrenic symptoms and dietary intake of N-3 fatty acids. Schizophr Res. 18:1995;85-86
30. Nohria V., Vaddadi K.S. Tardive dyskinesia and essential fatty acids: an animal model study. Horrobin D.F. Clinical uses of essential fatty acids. 1982;199-204 Eden Press, Montreal, Canada
31. Costall B.M., Kelly E., Naylor R.J. The antidyskinetic action of dihomo-gamma-linolenic acid in rodent. Br J Pharmacol. 83:1984;733-740
32. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 27:1989;313-323
33. Nilsson A., Horrobin D.F., Rosengren A., Waller L., Adlerberth A., Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population: a study of men born in 1933. Prostaglandins Leukot Essent Fatty Acids. 55:1996;83-87
34. Vaddadi K. Essential fatty acids and movement disorders. Peet M., Glen I., Horrobin D.F. Phospholipids spectrum disorders in psychiatry. 1999;285-296 Marius Press, Carnforth, UK
35. Vaddadi K.S. Dyskinesias and their treatment with essential fatty acids. Prostaglandins Leukot Essen Fatty Acids. 55:1996;89-94
36. Vaddadi K.S., Soosai E., Chiu E., Dingjan P. A randomized, placebo-controlled, double-blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport. 13:2002;29-33
37. Puri B.K., Bydder G.M., Counsell S.J., et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport. 13:2002;1-4
38. Vaddadi K. Essential fatty acids in the treatment of Huntington's disease. Peet M., Glen I., Horrobin D.F. Phospholipids spectrum disorders in psychiatry and neurology. 2nd ed.:2003;565-574 Marius Press, Carnforth, UK
39. Clifford J.J., Drago J., Natoli A.L., et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience. 109:2002;81-88
40. Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch SM, et al. Ethyl-eicosapentaenoate (ethyl-EPA) in Huntington's disease. A randomized placebo controlled trial. Am Coll Neurol 2004 (in press).
41. Harding A., Hsu V., Kornfeld K., Hancock J.F. Identification of residues and domains of Raf important for function in vivo and in vitro. J Biol Chem. 278:2003;45519-45527
42. von Gise A., Lorenz P., Wellbrock C., Hemmings B., Berberich-Siebelt F., Rapp U.R., Troppmair J. Apoptosis suppression by Raf-1 and MEK1 requires MEK-and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol. 21:2001;2324-2336
43. Bonventre J.V., Kyriakis J.M., Spech R., Witzgall R., Force T. Phospholipase A(2) and lipids as potential modulators of c-Raf 1 kinase. Am J Ther. 3:1996;287-293
44. Kim H.-Y., Akbar M., Lau A., Edsall L. Inhibition of neuronal apoptosis by docosahexaenoic acid (22: 6 n-3). J Biol Chem. 275:2000;35215-35223
45. Martin D.S.D., Lonergan P.E., Boland B., et al. Apoptotic changes in the aged brain are triggered by interlukin-1β-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. J Biol Chem. 277:2002;34239-34246
46. Lonergan P.E., Martin D.S.D., Horrobin D.F., Lynch M.A. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to γ-irradiation. J Biol Chem. 277:2002;20804-20811
47. Reddy M.A., Pushpa-Rekha T., Lanting L., Nadler J.L., Fatima S., Natarajan R. The oxidized lipid and lipoxygenase product 12(S)- hydroxyeicosatetraenoic acid induces hypertrophy and fibronectin transcription in vascular smooth muscle cells via p38 MAPK and cAMP response element-binding protein activation. J Biol Chem. 277:2002;9920-9928
48. Rudnick D.A., Perlmutter D.H., Muglia L.J. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA. 98:2001;8885-8890
49. Das U.N. Long-chain polyunsaturated fatty acids in the growth and development of the brain and memory. Nutrition. 19:2003;62-65
50. Rockwell P., Yuan H., Magnusson R., Figueiredo-Pereira M.E. Proteasome inhibition of neuronal cells induces proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch Biochem Biophys. 374:2000;325-333
51. Whitehouse A.S., Tisdale M.J. Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation. Biochem Biophys Res Commun. 285:2001;598-602
52. Das U.N. A perinatal strategy for preventing adult disease: the role of long-chain polyunsaturated fatty acids. 2002;Kluwer Academic Publishers, Boston
53. Ramesh G., Das U.N., Koratkar R., Padma M., Sagar P.S. Effect of essential fatty acids on tumor cells. Nutrition. 8:1992;343-347
54. Murphy M.G., Byczko Z. Effects of membrane polyunsaturated fatty acids on adenosine receptor function in intact N1E-115 neuroblastoma cells. Biochem Cell Biol. 68:1990;392-395